TREATMENT OF DISEASES ASSOCIATED WITH APOLIPOPROTEIN-A1, BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT OF APOLIPOPROTEIN-A1

摘要

1. A method for modulating the function and / or expression of an apolipoprotein polynucleotide (ApoA1) in cells or tissues of a patient in vivo or in vitro, which includes:! bringing said cells or tissues into contact with an antisense oligonucleotide from 5 to 30 nucleotides in length, where the sequence of said oligonucleotide is at least 50% identical to the inverse complement of a polynucleotide containing 5 to 30 consecutive nucleotides from nucleotides 1-932 of the sequence SEQ ID NO: 2 (Figure 8); what is the modulation of the function and / or expression of the apolipoprotein polynucleotide (ApoA1) in the cells or tissues of the patient in vivo or in vitro. ! 2. A method for modulating the function and / or expression of an apolipoprotein polynucleotide (ApoA1) in an in vivo or in vitro cell or tissue of a patient, which comprises:! bringing said cells or tissues into contact with an antisense oligonucleotide from 5 to 30 nucleotides in length, where the sequence of said oligonucleotide is at least 50% identical to the inverse complement of the antisense sequence of the apolipoprotein polynucleotide (ApoA1); what is the modulation of the function and / or expression of the apolipoprotein polynucleotide (ApoA1) in the cells or tissues of the patient in vivo or in vitro. ! 3. A method for modulating the function and / or expression of an apolipoprotein polynucleotide (ApoA1) in cells or tissues of a patient in vivo or in vitro, which includes:! bringing said cells or tissues into contact with an antisense oligonucleotide from 5 to 30 nucleotides in length, where the sequence of said oligonucleotide is at least 50% identical to the sequence of the antisense oligonucleotide of the apolipoprotein (ApoA1) polynucleotide; than